| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | captopril (Noyada®) |
| Formulation | 5 mg/5 ml and 25 mg/5 ml oral solution |
| Reference number | 2231 |
| Indication | Treatment of hypertension. Treatment of chronic heart failure with reduction of systolic ventricular function, in combination with diuretics and, when appropriate, digitalis and beta-blockers. Short-term (four weeks) treatment in any clinically stable patient within the first 24 hours of a myocardial infarction. Long-term prevention of symptomatic heart failure in clinically stable patients with asymptomatic left ventricular dysfunction (ejection fraction equal to or below 40%). Treatment of macroproteinuric diabetic nephropathy in patients with type I diabetes |
| Company | Martindale Pharma |
| BNF chapter | Cardiovascular system |
| Submission type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 03/12/2013 |